{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:13:05Z","timestamp":1790777585264,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Adenovirus type 7 (HAdV7) is one of the most pathogenic human adenoviruses (HAdVs) and can cause severe illness and even death, particularly in people with weakened immune systems. Many countries worldwide have experienced epidemics of this highly contagious pathogen, including China and Sierra Leone; however, studies describing the seroprevalence of anti-HAdV7 neutralizing antibodies (nAbs) are still lacking. Herein, we established an efficient neutralization assay based on a recombinant luciferase-expressing HAdV7 virus (HAd7-Luc) to monitor historical HAdV7 infections and predict outbreak distributions. Among the 2,350 serum samples collected from eight sites in China and Sierra Leone in this cross-sectional serological survey, the overall proportion of anti-HAdV7-seropositive individuals was nearly 60%, with higher seroprevalence rates in Sierra Leone than in China. Regionally, HAdV7 nAb titers were higher in China than in Sierra Leone and showed a geographic variation across different regions. Regardless of the location, the seropositive rate of HAdV7 nAb was lower than that of HAdV5 nAb, as was the nAb titer. The prevalence rates of antibodies against HAdV7 and HAdV5 were both related to age but not to sex. In addition, serologic cross-reactions were rarely observed among people infected with HAdV7 and HAdV5. These results indicate a humoral immune response acquired through endemic HAdV7 infection and enrich the understanding of not only the epidemiological prevention and control of HAdV7 but also the clinical application of HAdV7-based vaccines or gene therapy tools.<\/jats:p>","DOI":"10.3389\/fpubh.2023.1095343","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T05:09:51Z","timestamp":1675660191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A seroepidemiological survey of adenovirus type 7 circulation among healthy adults in China and in Sierra Leone, West Africa"],"prefix":"10.3389","volume":"11","author":[{"given":"Busen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0232092","DOI":"10.1371\/journal.pone.0232092","article-title":"Genetic variability of human adenovirus type 7 circulating in mainland China","volume":"15","author":"Cai","year":"2020","journal-title":"PLoS ONE."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0121375","DOI":"10.1371\/journal.pone.0121375","article-title":"Adenoviruses associated with acute respiratory diseases reported in Beijing from 2011 to 2013","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS ONE"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3201\/eid2206.151898","article-title":"USA, 2013\u20132014","volume":"22","author":"ith","year":"2016","journal-title":"Emerg Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jmv.20778","article-title":"Molecular epidemiology of human adenovirus isolated from children hospitalized with acute respiratory infection in S\u00e3o Paulo, Brazil","volume":"79","author":"Moura","year":"2007","journal-title":"J Med Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s10096-011-1406-8","article-title":"Detection of three human adenovirus species in adults with acute respiratory infection in China","volume":"31","author":"Guo","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00705-014-2308-8","article-title":"Epidemical features of HAdV-3 and HAdV-7 in pediatric pneumonia in Chongqing, China","volume":"160","author":"Wo","year":"2015","journal-title":"Arch Virol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12879-018-3651-2","article-title":"Human adenovirus type 7 infection causes a more severe disease than type 3","volume":"19","author":"Fu","year":"2019","journal-title":"BMC Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10096-007-0416-z","article-title":"Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature","volume":"27","author":"Hakim","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1743-422X-8-23","article-title":"Adenovirus serotype 7 associated with a severe lower respiratory tract disease outbreak in infants in Shaanxi Province, China","volume":"8","author":"Tang","year":"2011","journal-title":"Virol J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3201\/eid2204.151595","article-title":"Vietnam, 2014","volume":"22","author":"Measles-Associated","year":"2016","journal-title":"Emerg Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3201\/eid1811.120629","article-title":"Community outbreak of adenovirus, Taiwan, 2011","volume":"18","author":"Tsou","year":"2012","journal-title":"Emerg Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0232948","DOI":"10.1371\/journal.pone.0232948","article-title":"Epidemiological analysis of an outbreak of an adenovirus type 7 infection in a boot camp in China","volume":"15","author":"Guo","year":"2020","journal-title":"PLoS ONE."},{"key":"B13","first-page":"2331","article-title":"Epidemiology and transmission characteristics of human adenovirus type 7 caused acute respiratory disease outbreak in military trainees in East China","volume":"8","author":"Cheng","year":"2016","journal-title":"Am J Transl Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0172519","DOI":"10.1371\/journal.pone.0172519","article-title":"An outbreak of acute respiratory disease caused by a virus associated RNA II gene mutation strain of human adenovirus 7 in China, 2015","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS ONE"},{"key":"B15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3201\/eid1105.041211","article-title":"Adenovirus type 7 peptide diversity during outbreak, Korea, 1995\u20132000","volume":"11","author":"Choi","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3201\/eid1805.110865","article-title":"Human adenovirus type 7 outbreak in police training center, Malaysia","volume":"18","author":"Yusof","year":"2012","journal-title":"Emerg Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7883\/yoken.67.105","article-title":"Impact of human adenovirus serotype 7 in hospitalized children with severe fatal pneumonia in the Philippines","volume":"67","author":"Yamamoto","year":"2014","journal-title":"Jpn J Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"ofz017","DOI":"10.1093\/ofid\/ofz017","article-title":"Respiratory illness associated with emergent human adenovirus genome type 7d, New Jersey, 2016\u20132017","volume":"6","author":"Killerby","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/infdis\/jiz060","article-title":"Outbreak of respiratory illness associated with human adenovirus type 7 among persons attending Officer Candidates School, Quantico, Virginia, 2017","volume":"221","author":"Bautista-Gogel","year":"2020","journal-title":"J Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1128\/JCM.02517-14","article-title":"Human adenovirus type 7 infection associated with severe and fatal acute lower respiratory illness and nosocomial transmission","volume":"53","author":"Cui","year":"2015","journal-title":"J Clin Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1086\/319210","article-title":"Outbreak of adenovirus genome type 7d2 infection in a pediatric chronic-care facility and tertiary-care hospital","volume":"32","author":"Gerber","year":"2001","journal-title":"Clin Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/0196-6553(86)90100-8","article-title":"Outbreak of fatal adenoviral type 7a respiratory disease in a children's long-term care inpatient facility","volume":"14","author":"Alpert","year":"1986","journal-title":"Am J Infect Control."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM197206152862403","article-title":"Fatal pneumonia associated with adenovirus type 7 in three military trainees","volume":"286","author":"Dudding","year":"1972","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41426-018-0206-y","article-title":"Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa","volume":"7","author":"Wang","year":"2018","journal-title":"Emerg Microbes Infect."},{"key":"B25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1038\/emi.2017.29","article-title":"Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China","volume":"6","author":"Zheng","year":"2017","journal-title":"Emerg Microbes Infect."},{"key":"B28","first-page":"15","volume":"3","author":"Zha","year":"1995","journal-title":"EXperimental and virology. Invest Neutraliz Antibod Adenoviruses Pop"},{"key":"B29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/0959-437x(93)90126-a","article-title":"Gene therapy: adenovirus vectors","volume":"3","author":"Kozarsky","year":"1993","journal-title":"Curr Opin Genet Dev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1574-6968.2001.tb10703.x","article-title":"Viral vectors as potential HIV-1 vaccines","volume":"200","author":"Schnell","year":"2001","journal-title":"FEMS Microbiol Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine."},{"key":"B32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.micinf.2005.05.023","article-title":"Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis","volume":"8","author":"Appaiahgari","year":"2006","journal-title":"Microbes Infect."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e3577","DOI":"10.1097\/MD.0000000000003577","article-title":"Molecular epidemiology and clinical manifestations of adenovirus respiratory infections in Taiwanese children","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/S2214-109X(16)30367-9","article-title":"Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"5","author":"Li","year":"2017","journal-title":"Lancet Glob Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"Sprangers","year":"2003","journal-title":"J Clin Microbiol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1095343\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T05:09:55Z","timestamp":1675660195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1095343\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":39,"alternative-id":["10.3389\/fpubh.2023.1095343"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1095343","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"article-number":"1095343"}}